Ettel Keifman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ettel Keifman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Rosario Moratalla
Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
2 shared publications Camila Coll
1 shared publication- Camila L. Zold
Univ Buenos Aires, Sch Med, Dept Physiol & Biophys, Neural Circuit Physiol Lab,Syst Neurosci Grp, 2155 Paraguay St, RA-1121 Buenos Aires, DF, Argentina
1 shared publication - Camila Lidia Zold
Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO-Houssay), Grupo de Neurociencia de Sistemas, Universidad de Buenos Aires y Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires 1121, Argentina
1 shared publication - Diego Esteban Pafundo
Universidad de Buenos Aires y Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Fisiología y Biofísica "Bernardo Houssay" (IFIBIO-Houssay), Grupo de Neurociencia de Sistemas, Buenos Aires 1121, Argentina
1 shared publication - Irene Ruiz-DeDiego
Instituto Cajal, Consejo Superior de Investigaciones Científicas, CSIC, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S492
ROLE OF D2 DOPAMINE RECEPTORS AND THE STRIATOPALLIDAL PATHWAY IN A MOUSE MODEL OF L-DOPA-INDUCED DYSKINESIA
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S492
Open AccessROLE OF D2 DOPAMINE RECEPTORS AND THE STRIATOPALLIDAL PATHWAY IN A MOUSE MODEL OF L-DOPA-INDUCED DYSKINESIA
- Open Access
- 21 March 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (13) , 2146-2161
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L‐DOPA in a mouse model of Parkinson's disease
Background and Purpose: L‐DOPA‐induced dyskinesia (LID) remains a major complication of L‐DOPA therapy in Parkinson's disease. LID is believed to result from inhibition of substantia nigra reticulata (SNr) neurons by GABAergic striatal projection neurons that become supersensitive to dopamine receptor stimulation after severe nigrostriatal degeneration. Here, we asked if stimulation of direct medium spiny neuron (dMSN) GABAergic terminals at the SNr can produce a full dyskinetic state similar to that induced by L‐DOPA.Experimental Approach: Adult C57BL6 mice were lesioned with 6‐hydroxydopamine in the medial forebrain bundle. Channel rhodopsin was expressed in striatonigral terminals by ipsilateral striatal injection of adeno‐associated viral particles under the CaMKII promoter. Optic fibres were implanted on the ipsilateral SNr. Optical stimulation was performed before and 24 hr after three daily doses of L‐DOPA at subthreshold and suprathreshold dyskinetic doses. We also examined the combined effect of light stimulation and an acute L‐DOPA challenge.Key Results: Optostimulation of striatonigral terminals inhibited SNr neurons and induced all dyskinesia subtypes (optostimulation‐induced dyskinesia [OID]) in 6‐hydroxydopamine animals, but not in sham‐lesioned animals. Additionally, chronic L‐DOPA administration sensitised dyskinetic responses to striatonigral terminal optostimulation, as OIDs were more severe 24 hr after L‐DOPA administration. Furthermore, L‐DOPA combined with light stimulation did not result in higher dyskinesia scores than OID alone, suggesting that optostimulation has a masking effect on LID.Conclusion and Implications: This work suggests that striatonigral inhibition of basal ganglia output (SNr) is a decisive mechanism mediating LID and identifies the SNr as a target for managing LID.
- 21 March 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (13) , 2146-2161
Open AccessOptostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L‐DOPA in a mouse model of Parkinson's disease
Background and Purpose: L‐DOPA‐induced dyskinesia (LID) remains a major complication of L‐DOPA therapy in Parkinson's disease. LID is believed to result from inhibition of substantia nigra reticulata (SNr) neurons by GABAergic striatal projection neurons that become supersensitive to dopamine receptor stimulation after severe nigrostriatal degeneration. Here, we asked if stimulation of direct medium spiny neuron (dMSN) GABAergic terminals at the SNr can produce a full dyskinetic state similar to that induced by L‐DOPA.Experimental Approach: Adult C57BL6 mice were lesioned with 6‐hydroxydopamine in the medial forebrain bundle. Channel rhodopsin was expressed in striatonigral terminals by ipsilateral striatal injection of adeno‐associated viral particles under the CaMKII promoter. Optic fibres were implanted on the ipsilateral SNr. Optical stimulation was performed before and 24 hr after three daily doses of L‐DOPA at subthreshold and suprathreshold dyskinetic doses. We also examined the combined effect of light stimulation and an acute L‐DOPA challenge.Key Results: Optostimulation of striatonigral terminals inhibited SNr neurons and induced all dyskinesia subtypes (optostimulation‐induced dyskinesia [OID]) in 6‐hydroxydopamine animals, but not in sham‐lesioned animals. Additionally, chronic L‐DOPA administration sensitised dyskinetic responses to striatonigral terminal optostimulation, as OIDs were more severe 24 hr after L‐DOPA administration. Furthermore, L‐DOPA combined with light stimulation did not result in higher dyskinesia scores than OID alone, suggesting that optostimulation has a masking effect on LID.Conclusion and Implications: This work suggests that striatonigral inhibition of basal ganglia output (SNr) is a decisive mechanism mediating LID and identifies the SNr as a target for managing LID.
- 1 April 2014
- Published by Elsevier in Basal Ganglia
- Vol. 3 (4) , 203-212
Oscillations in the basal ganglia in Parkinson's disease: Role of the striatum
- 1 April 2014
- Published by Elsevier in Basal Ganglia
- Vol. 3 (4) , 203-212
Oscillations in the basal ganglia in Parkinson's disease: Role of the striatum